Vaccine Adjuvants Market Size
The Global Vaccine Adjuvants Market reached USD 739.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1,819.2 million by 2031. The global vaccine adjuvants market is expected to exhibit a CAGR of 12.2% during the forecast period (2024-2031).
Innovation in technologies will create a big opportunity for vaccine adjuvants market growth. For instance, the use of nanoparticles as adjuvants have been gaining attention in recent years. Nanoparticles can be designed to carry vaccine antigens and adjuvants, providing targeted delivery to immune cells and enhancing the immune response.
Growing awareness about vaccination and immunization programs, inclusion in the national immunization schedule, growing public awareness and support from government and non-government agencies, the emergence of chronic diseases, and the high prevalence of infectious & zoonotic diseases are major factors accelerating the growth of the global vaccine adjuvants market.
Market Summary
| Metrics | Details |
| CAGR | 12.2% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Product Type, Route of Administration, Disease, End User and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Vaccine Adjuvants Market Dynamics
Increasing prevalence of chronic diseases is driving the market growth
The global vaccine adjuvant market is expected to witness significant growth during the forecast period due to an increase in the incidence of chronic diseases, including infectious and vector-borne diseases, as well as cancer. According to a 2022 World Health Organization report, chronic diseases resulted in 41 million deaths worldwide, with cardiovascular disease being the leading cause of death (17.9 million), followed by cancer (9.3 million).
Moreover, the number of people with diabetes in emerging economies is expected to rise from 84 million in 1995 to 228 million in 2025, resulting in significant public health challenges. As a result, there is a growing demand for fast and accurate diagnosis, leading to increased demand for vaccine adjuvants.
Innovation in technologies will create big opportunity for vaccine adjuvants market growth
The rapid innovation and developments in technologies will create optimum vaccine adjuvants market opportunities for the vaccine manufacturers, while simultaneously potentially solving major antigen supply problems for pandemic planners and those involved in biodefense.
Nanoparticles can be designed to carry vaccine antigens and adjuvants, providing targeted delivery to immune cells and enhancing the immune response. Other innovations include the use of new types of adjuvants, such as toll-like receptor agonists, which activate immune cells in a specific way to enhance the immune response.
The side effects and high toxicity of adjuvants are restraining factors affecting the market growth
The primary challenge of most adjuvants for human use is toxicity. Toxicity not only poses a significant obstacle during the development and manufacturing stages but also increases the financial burden on market players. As a result, the adverse effects of adjuvant toxicity on vaccine manufacturing cost and vaccine safety profiles are impeding the growth of the global vaccine adjuvants market.
Vaccine Adjuvants Market Segment Analysis
The global vaccine adjuvants market is segmented based on product type, route of administration, disease, end user, and region.
The intramuscular segment is expected to hold dominant position in the global vaccine adjuvants market.
In route of administration segment, the intramuscular segment is expected to account for the highest market share of about 31.4% over the forecast period. This is owing to factors such as the rapidly growing geriatric population and vaccines for improved immunization. Intramuscular adjuvant injection induces adjuvant-specific cell influx in muscle. Adjuvants induce a transient pro-inflammatory milieu in muscle.
Vaccine Adjuvants Market Geographical Share
North America to dominate the global vaccine adjuvants market
North America is expected to hold a dominant position in the global vaccine adjuvants market holding 1/3rd of the total market, owing to the factors such as the presence of key market players, the availability of advanced technology, and the growing investment in the research and development of vaccines. The market growth is boosted by several immunization programs, government and non-government initiatives, and increased demand for combined vaccines.
Vaccine Adjuvants Manufacturers
The major global players in the market include InvivoGen, OZ Biosciences, SEPPIC, SPI Pharma, Agenus, Inc, Aphios Corp, Vaxine Pty Ltd, Seqirus, Chemtrade, and Croda International.
COVID-19 Impact on Market
The COVID-19 pandemic has had a significant impact on the global vaccine adjuvants market. The urgent need for effective vaccines to combat the virus has led to an unprecedented demand for adjuvants and other vaccine components, as well as increased funding for research and development in this field. Vaccines such as Pfizer-BioNTech and Moderna COVID-19 vaccines use lipid nanoparticle adjuvants to improve their delivery and stimulate a stronger immune response.
However, the pandemic has also had some negative impacts on the vaccine adjuvants market. Supply chain disruptions and manufacturing challenges have led to delays in the production and distribution of some adjuvants and other vaccine components. Therefore, Covid-19 had a mixed impact on this market.
Russia Ukraine Conflict Analysis
The ongoing conflict between Russia and Ukraine could potentially have an impact on the global vaccine adjuvants market. Russia is a major supplier of aluminum hydroxide, one of the most commonly used adjuvants in vaccines. The conflict between these two countries could potentially disrupt the supply chains for these adjuvants, which could have a negative impact on the availability of vaccines that use these adjuvants.
Key Developments
- In April 2022, GSK, a global biopharma company and SK bioscience, a vaccine manufacturing company, submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione, following positive Phase III clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant.
- In July 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.
- In December 2022, Evonik launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene in the market for use in adjuvants in parenteral dosage forms.
Why Purchase the Report?
- To visualize the global vaccine adjuvants- market segmentation based on product type, route of administration, diseases, end user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global vaccine adjuvants market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global vaccine adjuvants market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
